The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1539
L-Glutamine (Endari) for Sickle Cell Disease
The full article is available to subscribers Subscriber Login   

The FDA has approved an oral powder formulation of the amino acid L-glutamine (Endari – Emmaus) to reduce the acute complications of sickle cell disease in patients ≥5 years old. Endari is only the second drug to be approved for use in sickle cell disease; the antimetabolite hydroxyurea (Droxia) was approved 20 years ago. L-glutamine oral powder is also available by prescription as NutreStore for treatment of short bowel syndrome and over the counter as a dietary supplement.

SICKLE CELL DISEASE — The elongated or sickle-shaped red blood cells of sickle cell disease obstruct small blood vessels, causing ischemic tissue injury, episodes of severe pain (sickle cell crises), and many other complications. The only other available treatments have been hydroxyurea and chronic transfusions. Hydroxyurea, which increases fetal hemoglobin levels, has reduced the number of painful ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: L-Glutamine (Endari) for Sickle Cell Disease
Article code: 1539c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian